Insight Capital Research & Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Insight Capital Research & Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-114,725	Closed	-$2.79M	–	119
2014 Q1	$2.79M	Sell	114,725 -50	-0%	-$1.26K	0.64%	63
2013 Q4	$2.87M	Sell	114,775 -14,882	-11%	-$351K	0.64%	61
2013 Q3	$2.95M	Sell	129,657 -222,471	-63%	-$4.65M	0.71%	49
2013 Q2	$6.39M	Buy	+352,128	New	+$4.85M	1.66%	9

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Insight Capital Research & Management's ACAD Position: Q2 2014 in Review

Insight Capital Research & Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2014, closing a stake of 114,725 shares — an estimated $2.79M sold.

Insight Capital Research & Management first reported a position in ACAD in Q2 2013 and held it in 4 quarters. The position peaked at $6.39M in Q2 2013. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

Insight Capital Research & Management reported no remaining Acadia Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Insight Capital Research & Management sold 114,725 Acadia Pharmaceuticals shares in Q2 2014, an estimated $2.79M.
Insight Capital Research & Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Insight Capital Research & Management's Acadia Pharmaceuticals position peaked at $6.39M in Q2 2013.
160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on Insight Capital Research & Management's 13F filing for Q2 2014, filed 13 Aug 2014.